Melarsoprol Sensitivity Profile of Trypanosoma brucei gambiense Isolates from Cured and Relapsed Sleeping Sickness Patients from the Democratic Republic of the Congo

PLoS Neglected Tropical Diseases

Volumn 8, Issue 10, 2014, Pages

  Pyana Pati, Patient ^a   Van Reet, Nick ^b   Mumba Ngoyi, Dieudonné ^a   Ngay Lukusa, Ipos ^a   Karhemere Bin Shamamba, Stomy ^a   Büscher, Philippe ^b  

^a Institut National de Recherche Biomédicale   (Congo)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAGLYCEROPORIN; MELARSOPROL; PENTAMIDINE; ANTITRYPANOSOMAL AGENT; CHIMERIC PROTEIN; PROTOZOAL DNA;

AFRICAN TRYPANOSOMIASIS; ANIMAL MODEL; ARTICLE; CONGO; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE LOCUS; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PARASITE ISOLATION; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME; TRYPANOSOMA; ADULT; ANIMAL; CHEMISTRY; DEMOCRATIC REPUBLIC CONGO; DNA SEQUENCE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PARASITOLOGY; RECURRENT DISEASE; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

ADULT; ANIMALS; AQUAGLYCEROPORINS; BASE SEQUENCE; DEMOCRATIC REPUBLIC OF THE CONGO; DNA, PROTOZOAN; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MELARSOPROL; MICE; MOLECULAR SEQUENCE DATA; MUTANT CHIMERIC PROTEINS; MUTATION; PENTAMIDINE; PHENOTYPE; RECURRENCE; SEQUENCE ANALYSIS, DNA; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 84920118789     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003212     Document Type: Article

References (37)

1. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG, (2011) The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000–2009: the way forward. PLoS Negl Trop Dis 5: e1007.
2. Bacchi CJ, (2009) Chemotherapy of human African trypanosomiasis. Interdiscip Perspect Infect Dis 2009: 195040.
3. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J, (2012) Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 139: 842–846.
4. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56–64.
5. Stanghellini A, Josenando T, (2001) The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 6: 330–334.
6. Legros D, Fournier C, Gastellu Etchegorry M, Maiso F, Szumilin E, (1999) Echecs thérapeutiques du mélarsoprol parmi des patients traités au stade tardif de trypanosomose humaine africaine à T. b. gambiense en Ouganda. Bull Soc Pathol Exot Fil 92: 171–172.
7. Brun R, Schumacher R, Schmid C, Kunz C, Burri C, (2001) The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 6: 906–914.
8. Mumba Ngoyi D, Lejon V, Pyana P, Boelaert M, Ilunga M, et al. (2010) How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness? J Infect Dis 201: 453–463.
9. Maina N, Maina KJ, Mäser P, Brun R, (2007) Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure. Acta Trop 104: 84–90.
10. Robays J, Nyamowala G, Sese C, Kande Betu-Ku-Mesu V, Lutumba P, et al. (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Em Inf Dis 14: 966–967.
11. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, et al. (2001) Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 6: 407–411.
12. Burri C, Keiser J, (2001) Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 6: 412–420.
13. Nerima B, Matovu E, Lubega GW, Enyaru JC, (2007) Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction. Trop Med Int Health 12: 1361–1368.
14. Matovu E, Stewart ML, Geiser F, Brun R, Mäser P, et al. (2003) Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2: 1003–1008.
15. Matovu E, Geiser F, Schneider V, Mäser P, Enyaru JCK, et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117: 73–81.
16. Claes F, Vodnala SK, Van Reet N, Boucher N, Lunden-Miguel H, et al. (2009) Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness patients. PLoS Negl Trop Dis 3: e486.
17. Mäser P, Sütterlin C, Kralli A, Kaminsky R, (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242–244.
18. Bridges DJ, Gould MK, Nerima B, Mäser P, Burchmore RJS, et al. (2007) Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamine drugs in African trypanosomes. Mol Pharmacol 71: 1098–1106.
19. Baker N, Glover L, Munday JC, Aguinaga Andrés D, Barrett MP, et al. (2012) Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci USA 109: 10996–11001.
20. Graf FE, Ludin P, Wenzler T, Kaiser M, Brun R, et al. (2013) Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates concur with decreased susceptibility to pentamidine and melarsoprol. PLoS Negl Trop Dis 7: e2475.
21. Pépin J, Ethier L, Kazadi C, Milord F, Ryder R, (1992) The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg 47: 133–140.
22. Pépin J, Mpia B, Iloasebe M, (2002) Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment. Trans R Soc Trop Med Hyg 96: 421–426.
23. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D, (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93: 439–442.
24. Munday JC, Eze AA, Baker N, Glover L, Clucas C, et al. (2014) Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. J Antimicrob Chemother 69: 651–663.
25. Pyana PP, Ngay Lukusa I, Mumba Ngoyi D, Van Reet N, Kaiser M, et al. (2011) Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice. PLoS Negl Trop Dis 5: e1025.
26. Van Reet N, Van de Vyver H, Pyana PP, Van der Linden AM, Büscher P, (2014) A panel of Trypanosoma brucei strains tagged with blue and red shifted luciferases for bioluminescent imaging in murine infection models. PLoS Negl Trop Dis In press.
27. Büscher P, Mumba Ngoyi D, Kaboré J, Lejon V, Robays J, et al. (2009) Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis 3: e471.
28. Lanham SM, Godfrey DG, (1970) Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp Parasitol 28: 521–534.
29. Wirtz E, Hartmann C, Clayton C, (1994) Gene expression mediated by bacteriophage T3 and T7 RNA polymerase in transgenic trypanosomes. Nucleic Acids Res 22: 3887–3894.
30. Kibona SN, Matemba L, Kaboya JS, Lubega GW, (2006) Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania. Trop Med Int Health 11: 144–155.
31. Giroud C, Ottones F, Coustou V, Dacheux D, Biteau N, et al. (2009) Murine models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Negl Trop Dis 3: e509.
32. Burke J, (1971) Historique de la lutte contre la maladie du sommeil au Congo. Ann Soc Belg Méd Trop 51: 465–477.
33. Ollivier G, Legros D, (2001) Trypanosomiase humaine africaine: historique de la thérapeutique et ses échecs. Trop Med Int Health 6: 11–855.
34. Simo G, Herder S, Nijokou F, Asonganyi T, Tilley A, et al. (2005) Trypanosoma brucei s.l.: Characterisation of stocks from Central Africa by PCR analysis of mobile genetic elements. Exp Parasitol 110: 353–362.
35. Lejon V, Roger M, Mumba Ngoyi D, Menten J, Robays J, et al. (2008) Novel markers for treatment outcome in late stage T.b. gambiense trypanosomiasis. Clin Infect Dis 47: 15–22.
36. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C, (2004) Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364: 789–790.
37. Balasegaram M, Harris S, Checchi F, Hamel C, Karunakara U, (2006) Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull World Health Organ 84: 777–782.